[SunilNagpal]

FDA has very recently issued a warning on the use of SGLT2 inhibitors that are suspected to be linked to the fatal condition called KETOACIDOSIS.

SGLT-2 inhibitors (sodium-glucose cotransporter-2 inhibitors) like Canagliflozin, Dapagliflozin and Empagliflozin are reported to elevate blood ketones levels, which can lead to diabetic coma or even death!

Some brand names of these drugs include:

• Invokana (canagliflozin)
  
• Glyxambi (empagliflozin and linagliptin)
  
• Farxiga (dapagliflozin)
  
• Invokamet (canagliflozin and metformin)
  
• Xigduo XR (dapagliflozin and metformin)
  
• Jardiance (empagliflozin)
  

It is thus advised to patients of Type-2 diabetes to monitor their ketone levels (ketoacidosis) regulary while consuming SGLT-2 inhibitors. Symptoms like difficulty breathing, nausea, vomiting, abdominal pain, unusual fatigue or sleepiness, confusions should be immediately addressed.

Best wishes